These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 32252059)

  • 1. Polymorphisms in Glycolysis-Related Genes Are Associated with Clinical Outcomes of Paclitaxel-Cisplatin Chemotherapy in Non-Small Cell Lung Cancer.
    Choi SH; Jin CC; Do SK; Lee SY; Choi JE; Kang HG; Kim JH; Lee JH; Hong MJ; Lee WK; Jeong JY; Shin KM; Lee YH; Seo H; Yoo SS; Lee J; Cha SI; Kim CH; Park JY
    Oncology; 2020; 98(7):468-477. PubMed ID: 32252059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphisms in DNA repair and apoptosis-related genes and clinical outcomes of patients with non-small cell lung cancer treated with first-line paclitaxel-cisplatin chemotherapy.
    Lee SY; Kang HG; Yoo SS; Kang YR; Choi YY; Lee WK; Choi JE; Jeon HS; Shin KM; Oh IJ; Kim KS; Lee J; Cha SI; Kim CH; Kim YC; Park JY
    Lung Cancer; 2013 Nov; 82(2):330-9. PubMed ID: 23973201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy.
    Lee SY; Jung DK; Choi JE; Jin CC; Hong MJ; Do SK; Kang HG; Lee WK; Seok Y; Lee EB; Jeong JY; Shin KM; Yoo SS; Lee J; Cha SI; Kim CH; Park JY
    Sci Rep; 2016 May; 6():25952. PubMed ID: 27181838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized trial of TLR-2 agonist CADI-05 targeting desmocollin-3 for advanced non-small-cell lung cancer.
    Belani CP; Chakraborty BC; Modi RI; Khamar BM
    Ann Oncol; 2017 Feb; 28(2):298-304. PubMed ID: 27831503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer.
    Liao WY; Chen JH; Wu M; Shih JY; Chen KY; Ho CC; Yang JC; Yu CJ
    Clin Lung Cancer; 2013 Jul; 14(4):418-24. PubMed ID: 23291258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of GSTP1 and XRCC1 gene polymorphisms with clinical outcome of advanced non-small cell lung cancer patients with cisplatin-based chemotherapy.
    Han B; Guo Z; Ma Y; Kang S; Wang Y; Wei Q; Wu X
    Int J Clin Exp Pathol; 2015; 8(4):4113-9. PubMed ID: 26097600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RB1 polymorphism contributes to the efficacy of platinum-taxanes in advanced squamous cell lung cancer.
    Liu D; Xu W; Zhang ZW; Qian J; Zheng H; Zhang J; Su B
    Asian Pac J Cancer Prev; 2015; 16(2):775-81. PubMed ID: 25684524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetic analysis of advanced non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin chemotherapy.
    Park HS; Lim SM; Shin HJ; Cho A; Shin JG; Lee MG; Kim HR; Kim JH; Cho BC
    Pharmacogenet Genomics; 2016 Mar; 26(3):116-25. PubMed ID: 26641474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer.
    Paz-Ares L; Bálint B; de Boer RH; van Meerbeeck JP; Wierzbicki R; De Souza P; Galimi F; Haddad V; Sabin T; Hei YJ; Pan Y; Cottrell S; Hsu CP; RamLau R
    J Thorac Oncol; 2013 Mar; 8(3):329-37. PubMed ID: 23370314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial.
    Kubota K; Sakai H; Katakami N; Nishio M; Inoue A; Okamoto H; Isobe H; Kunitoh H; Takiguchi Y; Kobayashi K; Nakamura Y; Ohmatsu H; Sugawara S; Minato K; Fukuda M; Yokoyama A; Takeuchi M; Michimae H; Gemma A; Kudoh S;
    Ann Oncol; 2015 Jul; 26(7):1401-8. PubMed ID: 25908605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A genetic variation in microRNA target site of ETS2 is associated with clinical outcomes of paclitaxel-cisplatin chemotherapy in non-small cell lung cancer.
    Hong MJ; Lee SY; Choi JE; Jin CC; Kang HJ; Baek SA; Lee SY; Shin KM; Jeong JY; Lee WK; Yoo SS; Lee J; Cha SI; Kim CH; Son JW; Park JY
    Oncotarget; 2016 Mar; 7(13):15948-58. PubMed ID: 26893365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for patients with non-small cell lung cancer who could survive long term chemotherapy.
    Wu XY; Huang XE
    Asian Pac J Cancer Prev; 2015; 16(2):647-52. PubMed ID: 25684501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PDE3A is hypermethylated in cisplatin resistant non-small cell lung cancer cells and is a modulator of chemotherapy response.
    Tian FM; Zhong CY; Wang XN; Meng Y
    Eur Rev Med Pharmacol Sci; 2017 Jun; 21(11):2635-2641. PubMed ID: 28678321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy.
    Ozdemir O; Ozdemir P; Veral A; Uluer H; Ozhan MH
    Asian Pac J Cancer Prev; 2013; 14(8):4679-83. PubMed ID: 24083725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
    Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
    Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer.
    Nuijten MJ; Aultman R; Carpeño Jde C; Vergnenègre A; Chouaid C; Walzer S; Siebert U
    Curr Med Res Opin; 2011 Nov; 27(11):2193-201. PubMed ID: 21970659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
    Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
    Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VCP gene variation predicts outcome of advanced non-small-cell lung cancer platinum-based chemotherapy.
    Peng J; Yang LX; Zhao XY; Gao ZQ; Yang J; Wu WT; Wang HJ; Wang JC; Qian J; Chen HY; Jin L; Bai CX; Han BH; Wang WM; Lu DR
    Tumour Biol; 2013 Apr; 34(2):953-61. PubMed ID: 23412975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An expression quantitative trait locus variant for LKB1 gene predicts the clinical outcomes of chemotherapy in patients with non-small cell lung cancer.
    Seo H; Jung DK; Kang HG; Jeong JY; Lee SY; Choi JE; Hong MJ; Do SK; Lee JH; Lee WK; Shin KM; Yoo SS; Lee J; Cha SI; Kim CH; Park JY
    Cancer Genet; 2018 Dec; 228-229():73-82. PubMed ID: 30553476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prognostic-factor risk index in advanced non-small-cell lung cancer treated with cisplatin-containing combination chemotherapy.
    Shinkai T; Eguchi K; Sasaki Y; Tamura T; Ohe Y; Kojima A; Oshita F; Miya T; Okamoto H; Iemura K
    Cancer Chemother Pharmacol; 1992; 30(1):1-6. PubMed ID: 1316809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.